Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign Prostatic Hyperplasia

Study Identifier
191622-517
CT.gov Identifier
NCT00284518
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Men's Health
    • Study Drug
  • botulinum toxin Type A
  • normal saline
    • Phase
    Phase 2
    Sex
    Male
    Age
    50+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Lower urinary tract symptoms due to benign prostatic hyperplasia * Enlarged prostate volume by rectal ultrasound
    Exclusion Criteria:
    * Previous prostate surgery * Previous or current diagnosis of prostate cancer * Use of other medications for the treatment of prostatic hyperplasia * Urinary tract infection

    Protocol Summary

    The purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.

    Study Locations

    Location
    Status
    Location
    Murdoch, Australia
    Status
    Not applicable
    Location
    Vienna, Austria
    Status
    Not applicable
    Location
    Victoria, British Columbia, Canada
    Status
    Not applicable
    Location
    Olomouc, Czech Republic
    Status
    Not applicable
    Location
    Paris, France
    Status
    Not applicable
    Location
    Braunschweig, Germany
    Status
    Not applicable
    Showing {first} - {last} of {total} Results